Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX 11:57:44 2024-09-11 EDT 5-day change 1st Jan Change
114.50 USD -0.72% Intraday chart for Merck & Co., Inc. -0.86% +5.30%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Merck: positive results for HPV vaccine CF
Merck's HPV Vaccine Meets Main Goal in Phase 3 Study in Japanese Males MT
Phanes Therapeutics Doses First Patient in Trial of Pancreatic Cancer Treatment in Combination With Chemotherapy MT
Merck: positive results in certain lung cancers CF
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
US Equities Markets End Mixed Thursday as Investors Evaluate Job Growth Report MT
Sector Update: Health Care Stocks Fall Late Afternoon MT
Transcript : Merck & Co., Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 02:35 PM
Sector Update: Health Care Stocks Slide Thursday Afternoon MT
US Equity Indexes Mixed as Investors Eye Friday's Nonfarm Payrolls After Private Jobs Unexpectedly Slow Down MT
US Equity Indexes Mixed Following Surprise Deceleration in Private Jobs MT
Merck Completes Negotiations With Pan-Canadian Pharma Alliance MT
Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension CI
Merck to present advances in oncology CF
Merck: start of a trial in diabetic retinopathy CF
Merck, EyeBio Begin Phase 2b/3 Trial for Restoret MT
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 CI
Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret?? for the Treatment of Diabetic Macular Edema CI
Merck's Keytruda-Padcev Combination for Bladder Cancer Approved in EU MT
Merck: EU approves urothelial carcinoma treatment CF
European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults CI
US will still pay at least twice as much after negotiating drug prices RE
IO Biotech Gets Data Monitoring Committee Recommendation to Continue Phase 3 Melanoma Study MT
Merck to Discontinue 2 Phase 3 Trials on Keytruda MT
Merck: terminates two phase III trials on Keytruda CF
Chart Merck & Co., Inc.
More charts
Logo Merck & Co., Inc.
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (18%); - sale of animal health products (9.4%); - other (2.9%). Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Employees
71,000
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
115.33USD
Average target price
139.03USD
Spread / Average Target
+20.55%
Consensus
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.
  5. Merck, Orion Convert Ongoing Collaboration Into Exclusive Global License for Opevesostat
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW